FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898099134> ?p ?o ?g. }

• W2898099134 endingPage "S730" @default.
• W2898099134 startingPage "S730" @default.
• W2898099134 abstract "The analysis by immunohistochemistry (IHC) of the programmed cell death-ligand 1 (PD-L1) protein expression is the most extensively explored biomarker for response to immunotherapy in non-small cell lung cancer (NSCLC). However, there are differences concerning diverse IHC assays and cut-off criteria: Pembrolizumab with the 22C3 assay with cut-off ranges of >1%, 1-49% and >50%; and Nivolumab with the 28-8 assay and ranges of <1%, 1-5%, 5 -10% and >10%. Furthermore, there is lack of information regarding the association between the histological subtype of adenocarcinoma and PD-L1 expression. In this work, we assessed the frequency of PD-L1 expression according with to histological subtype of adenocarcinoma. PD-L1 expression was assessed using the PD-L1 IHC 22C3 pharmDx immunohistochemistry assay (Dako North America, Inc.). We correlated histological subtype of adenocarcinoma with the frequency and intensity of PD-L1 expression, smoking history, EGFR and ALK status. Tissue samples from one hundred and sixty-two were analyzed, of which 33 (20.4%) were excluded due to insufficient material for PD-L1asessment. Among them, 106 patients (71,55%) were female, the median age was 63 years (range 31-86 years), 69 (53.5%) were never-smokers with no exposition to wood smoke or asbestos (79,61.2% and 117, 90.7% respectively). Among the 129 adenocarcinomas, 31.0% were acinar histological subtype; 27.1% solid, 17.1% papillary, 3.9% lepidic, 1.6% micropapillary and 54.3% had a moderated tumor differentiation grade. According to PD-L1 score, 49 (38%) of the patients were classified as negative (PD-L1<1%), 71(55%) as poor PD-L1 expression (1 - 49%), and 9 (7%) as strong PD-L1 expression (≥50%). According to the IASLC/ATS adenocarcinoma histological subtype was associated with PD-L1 expression (p=0.003). Solid and acinar adenocarcinomas were more likely to present strong PD-L1 expression (55.6% and 33.3%, respectively) compared to lepidic, papillary, micropapillary and unspecified tumors, which presented a strong PD-L1 expression in up to 11.1%. Median PFS to first line therapy was 10.3 (95% CI: 6.1–14.5) months. Tobacco exposure was the only factor independently associated with an increase in the hazard of progression to first line therapy (either CT or TKI) from any cause among NSCLC patients (HR, 95% CI: 1.56-12.1). The median OS was 41.9 (95% CI: 10.9–72.9) months. Median OS differences were not found among PD-L1 (negative vs. positive: 60.6 vs. 31.3 months, p=0.685). Patients with adenocarcinoma tumors, solid histological subtype and poor differentiation grade can be more benefited with a PD-1 based immunotherapy. PD-L1 score can be a predictor factor for the response to first line chemotherapy." @default.
• W2898099134 created "2018-11-02" @default.
• W2898099134 creator A5003892684 @default.
• W2898099134 creator A5020080512 @default.
• W2898099134 creator A5033440068 @default.
• W2898099134 creator A5035063101 @default.
• W2898099134 creator A5036513860 @default.
• W2898099134 creator A5038527086 @default.
• W2898099134 creator A5042861285 @default.
• W2898099134 creator A5079912254 @default.
• W2898099134 creator A5083718330 @default.
• W2898099134 creator A5086340434 @default.
• W2898099134 date "2018-10-01" @default.
• W2898099134 modified "2023-09-26" @default.
• W2898099134 title "P2.04-01 Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells." @default.
• W2898099134 doi "https://doi.org/10.1016/j.jtho.2018.08.1225" @default.
• W2898099134 hasPublicationYear "2018" @default.
• W2898099134 type Work @default.
• W2898099134 sameAs 2898099134 @default.
• W2898099134 citedByCount "0" @default.
• W2898099134 crossrefType "journal-article" @default.
• W2898099134 hasAuthorship W2898099134A5003892684 @default.
• W2898099134 hasAuthorship W2898099134A5020080512 @default.
• W2898099134 hasAuthorship W2898099134A5033440068 @default.
• W2898099134 hasAuthorship W2898099134A5035063101 @default.
• W2898099134 hasAuthorship W2898099134A5036513860 @default.
• W2898099134 hasAuthorship W2898099134A5038527086 @default.
• W2898099134 hasAuthorship W2898099134A5042861285 @default.
• W2898099134 hasAuthorship W2898099134A5079912254 @default.
• W2898099134 hasAuthorship W2898099134A5083718330 @default.
• W2898099134 hasAuthorship W2898099134A5086340434 @default.
• W2898099134 hasBestOaLocation W28980991341 @default.
• W2898099134 hasConcept C121608353 @default.
• W2898099134 hasConcept C126322002 @default.
• W2898099134 hasConcept C142724271 @default.
• W2898099134 hasConcept C143998085 @default.
• W2898099134 hasConcept C204232928 @default.
• W2898099134 hasConcept C2776256026 @default.
• W2898099134 hasConcept C2777701055 @default.
• W2898099134 hasConcept C2780030458 @default.
• W2898099134 hasConcept C2780057760 @default.
• W2898099134 hasConcept C2781053074 @default.
• W2898099134 hasConcept C2781182431 @default.
• W2898099134 hasConcept C2781197716 @default.
• W2898099134 hasConcept C55493867 @default.
• W2898099134 hasConcept C71924100 @default.
• W2898099134 hasConcept C86803240 @default.
• W2898099134 hasConceptScore W2898099134C121608353 @default.
• W2898099134 hasConceptScore W2898099134C126322002 @default.
• W2898099134 hasConceptScore W2898099134C142724271 @default.
• W2898099134 hasConceptScore W2898099134C143998085 @default.
• W2898099134 hasConceptScore W2898099134C204232928 @default.
• W2898099134 hasConceptScore W2898099134C2776256026 @default.
• W2898099134 hasConceptScore W2898099134C2777701055 @default.
• W2898099134 hasConceptScore W2898099134C2780030458 @default.
• W2898099134 hasConceptScore W2898099134C2780057760 @default.
• W2898099134 hasConceptScore W2898099134C2781053074 @default.
• W2898099134 hasConceptScore W2898099134C2781182431 @default.
• W2898099134 hasConceptScore W2898099134C2781197716 @default.
• W2898099134 hasConceptScore W2898099134C55493867 @default.
• W2898099134 hasConceptScore W2898099134C71924100 @default.
• W2898099134 hasConceptScore W2898099134C86803240 @default.
• W2898099134 hasIssue "10" @default.
• W2898099134 hasLocation W28980991341 @default.
• W2898099134 hasOpenAccess W2898099134 @default.
• W2898099134 hasPrimaryLocation W28980991341 @default.
• W2898099134 hasRelatedWork W2091729697 @default.
• W2898099134 hasRelatedWork W2403923136 @default.
• W2898099134 hasRelatedWork W2615945276 @default.
• W2898099134 hasRelatedWork W2767114511 @default.
• W2898099134 hasRelatedWork W2786497694 @default.
• W2898099134 hasRelatedWork W2898071776 @default.
• W2898099134 hasRelatedWork W2981883049 @default.
• W2898099134 hasRelatedWork W3043416314 @default.
• W2898099134 hasRelatedWork W3215044659 @default.
• W2898099134 hasRelatedWork W4322754005 @default.
• W2898099134 hasVolume "13" @default.
• W2898099134 isParatext "false" @default.
• W2898099134 isRetracted "false" @default.
• W2898099134 magId "2898099134" @default.
• W2898099134 workType "article" @default.